Abstract
AbstractDopamine agonist withdrawal syndrome (DAWS) has recently been named in the Archives of Neurology. It describes a cluster of symptoms occurring in Parkinson's disease patients with impulse control disorders on tapering down or withdrawal of their dopamine agonist. Drs Lindahl and MacMahon discuss the risk factors for the development of DAWS and some approaches to its management. Copyright © 2011 Wiley Interface Ltd
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
